Erschienen in:
03.12.2019 | Special Article
Canadian Critical Care Society clinical practice guideline: The use of vasopressin and vasopressin analogues in critically ill adults with distributive shock
verfasst von:
Kimia Honarmand, MSc, MD, Kevin John Um, MD, Emilie P. Belley-Côté, MD PhD, Waleed Alhazzani, MD, MSc, Chris Farley, BHSc, MScPT, Shannon M. Fernando, MD, MSc, Kirsten Fiest, PhD, Donna Grey, Edita Hajdini, RN, Margaret Herridge, MD, MSc, Carmen Hrymak, MD, Morten Hylander Møller, MD, PhD, Salmaan Kanji, PharmD, François Lamontagne, MD, MSc, François Lauzier, MD, MSc, Sangeeta Mehta, MD, Bojan Paunovic, MD, Rohit Singal, MD, MSc, Jennifer Ly Tsang, MD, PhD, Christine Wynne, BSc, BScPhm, ACPR, Bram Rochwerg, MD, MSc
Erschienen in:
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Hemodynamic management of adults with distributive shock often includes the use of catecholamine-based vasoconstricting medications. It is unclear whether adding vasopressin or vasopressin analogues to catecholamine therapy is beneficial in the management of patients with distributive shock. The purpose of this guideline was to develop an evidence-based recommendation regarding the addition of vasopressin to catecholamine vasopressors in the management of adults with distributive shock.
Methods
We summarized the evidence informing this recommendation by updating a recently published meta-analysis. Then, a multidisciplinary panel from the Canadian Critical Care Society developed the recommendation using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.
Results
The updated systematic review identified 25 randomized controlled trials including a total of 3,737 patients with distributive shock. Compared with catecholamine therapy alone, the addition of vasopressin or its analogues was associated with a reduced risk of mortality (relative risk [RR], 0.91; 95% confidence interval [CI], 0.85 to 0.99; low certainty), reduced risk of atrial fibrillation (RR, 0.77; 95% CI, 0.67 to 0.88; high certainty), and increased risk of digital ischemia (RR, 2.56; 95% CI, 1.24 to 5.25; moderate certainty).
Conclusions
After considering certainty in the evidence, values and preferences, cost, and other factors, the expert guideline panel suggests using vasopressin or vasopressin analogues in addition to catecholamines over catecholamine vasopressors alone for the management of distributive shock (conditional recommendation, low certainty evidence).